INTS (Intensity Therapeutics, Inc. Common stock)
Insider Trading Activity
Every open-market purchase and sale reported by INTS officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-20 | MARK A GOLDBERG | Director | A | — | — |
| 2026-07-20 | Emer Leahy | Director | A | — | — |
| 2026-07-20 | LEWIS H BENDER | President and CEO | A | — | — |
| 2026-07-20 | Daniel Donovan | Director | A | — | — |
| 2026-07-20 | Joseph Talamo | Chief Financial Officer | A | — | — |
| 2026-07-20 | John M Wesolowski | Principal Accounting Officer | A | — | — |
| 2026-07-20 | THOMAS I H DUBIN | Director | A | — | — |
| 2026-07-01 | Joseph Talamo | Chief Financial Officer | A | — | — |
| 2026-07-01 | John M Wesolowski | Principal Accounting Officer | A | — | — |
| 2026-03-30 | LEWIS H BENDER | President and CEO | A | — | — |
| 2026-01-05 | John M Wesolowski | Principal Accounting Officer | A | — | — |
| 2026-01-05 | Joseph Talamo | Chief Financial Officer | A | — | — |
| 2025-07-02 | Joseph Talamo | Chief Financial Officer | A | — | — |
| 2025-07-02 | John M Wesolowski | Principal Accounting Officer | A | — | — |
| 2025-05-06 | Emer Leahy | Director | A | — | — |
| 2025-05-06 | LEWIS H BENDER | President and CEO | A | — | — |
| 2025-05-06 | Daniel Donovan | Director | A | — | — |
| 2025-05-06 | THOMAS I H DUBIN | Director | A | — | — |
| 2025-05-06 | MARK A GOLDBERG | Director | A | — | — |
| 2025-05-06 | John M Wesolowski | Principal Accounting Officer | A | — | — |
| 2025-05-06 | John M Wesolowski | Principal Accounting Officer | A | — | — |
| 2025-05-06 | Joseph Talamo | Chief Financial Officer | A | — | — |
| 2024-10-23 | Joseph Talamo | Chief Financial Officer | A | — | — |
| 2024-10-23 | John M Wesolowski | Principal Accounting Officer | A | — | — |
| 2024-06-07 | John M Wesolowski | Principal Accounting Officer | M | — | — |
| 2024-05-15 | THOMAS I H DUBIN | Director | A | — | — |
| 2024-03-07 | John M Wesolowski | See Remarks | A | — | — |
| 2024-03-07 | LEWIS H BENDER | President and CEO | A | — | — |
| 2024-03-07 | MARK A GOLDBERG | Director | A | — | — |
| 2024-03-07 | Daniel Donovan | Director | A | — | — |
| 2024-03-07 | Emer Leahy | Director | A | — | — |
| 2023-12-12 | Joseph Talamo | Chief Financial Officer | A | — | — |
| 2023-07-21 | John M Wesolowski | Interim CFO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 118,549 | — |
| — | Principal Accounting Officer | 7,102 | — |
| — | Chief Financial Officer | 2,239 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the INTS quote page; the site-wide leaderboard is on the insider transactions hub.